MedTrace Logo

Brain Markers of Anxiety Disorders and SSRI/CBT Treatment in Children and Adolescents

NCT01160588 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 156

Last updated 2015-05-27

No results posted yet for this study

Summary

This study will attempt to identify gene and brain activity markers that predict whether children and adolescents with anxiety disorders will respond to selective serotonin reuptake inhibitor medications or Cognitive Behavioral Therapy (CBT).

Conditions

  • Social Phobia
  • Generalized Anxiety Disorder
  • Separation Anxiety Disorder

Interventions

DRUG

Sertraline

Oral sertraline will be started at 25 mg/day, increasing on subsequent visits to 50, 75, 100, 125, 150, and 200mg/day) Unless adverse effects become problematic, the goal is for subjects to reach 200mg/day. Dosing of sertraline is flexible, based on tolerance (absence of side effects) and clinical response.

Sponsors & Collaborators

Principal Investigators

  • K. Luan Phan, M.D. · University of Michigan

Eligibility

Min Age
7 Years
Max Age
19 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2010-07-31
Primary Completion
2015-03-31
Completion
2015-03-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01160588 on ClinicalTrials.gov